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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.040Objective: Several studies have recently reported an association between aortic
valve calcification and atherosclerosis of the cardiovascular system, suggesting that
aortic valve calcification might represent an atherosclerosis-like process. Hence the
aim of the present study was to determine whether there is a similar association
between aortic stenosis and aortic atheromas.
Methods: We evaluated the records and echocardiographic videotapes of 91 con-
secutive patients with severe aortic stenosis who underwent intraoperative trans-
esophageal echocardiography before aortic valve replacement to measure the pres-
ence and characteristics of aortic atheromas. There were 50 men (55%) and 41
women (45%). The mean age was 71.9  9.4 years (range, 34-91 years). These
patients were compared with 91 sex-and age-matched patients without aortic ste-
nosis who underwent transesophageal echocardiography for various indications.
Aortic atheroma was defined as localized intimal thickening of 3 mm or larger. A
lesion was considered complex if there was a plaque extending 5 mm or more into
the aortic lumen; if the lesion was protruding, mobile, or ulcerated; or both.
Results: The aortic stenosis group had significantly higher rates of aortic atheromas
(85% vs 37%, P  .001) and complex atheromas (47% vs 9%, P  .001) compared
with the control group. In the vast majority of patients in the aortic stenosis group,
the aortic atheromas were localized in the aortic arch (60 [66%] patients, with 50%
being complex aortic atheromas) and in the descending aorta (70 [77%] patients,
with 45.7% being complex aortic atheromas); in only 4 (4.4%) patients, the aortic
atheromas were localized in the ascending aorta (50% complex aortic atheromas).
Conclusions: There is a strong association between the presence of severe aortic
stenosis and the presence and severity of aortic atheromas, suggesting that aortic
stenosis might be a manifestation of the atherosclerotic process. These findings
imply that (1) aggressive atherosclerotic risk-factor modification for patients with
aortic stenosis might be advisable and (2) consideration of evaluation of the aorta by
means of transesophageal echocardiography before aortic valve replacement in
selected patients might be helpful.
Calcific aortic stenosis (AS) has become the most common cardiac valvulardisease in developed countries, affecting 2% to 3% of the population by theage of 65 years.1,2 In the recently published European Heart Survey on
valvular disease comprising 5001 patients, AS was the most frequent, single, native,
left-sided valve disease, with 82% of the cases being of “degenerative” cause.1
The early lesions of degenerative AS have some similarities to arterial athero-
sclerosis plaques.3 Several studies have recently reported an association between
aortic valve calcification and atherosclerosis of the cardiovascular system, suggest-
ing that aortic valve calcification might represent an atherosclerosis-like process.4,5
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tion between atherosclerotic risk factors and aortic valve
disease.6,7
Hence the aim of the present study was to determine
whether there is a similar association between severe AS
and atherosclerosis of the thoracic aorta imaged by means of
transesophageal echocardiography (TEE).
Methods
Study Group
The study population was composed of 91 consecutive patients
with severe AS who underwent intraoperative TEE before aortic
valve replacement between January 1, 2002, and July 31, 2003, in
a single tertiary medical center. There were 50 men (55%) and 41
women (45%). The mean age was 71.9  9.4 years (range, 34-91
years). These patients were compared with 91 sex- and age-
matched patients (59 men and 32 women; mean age, 70.4  8.4
years; range, 44-90 years) without AS who underwent TEE for
various indications during the same period (control group). Indi-
cations for TEE referral in the control group were (1) evaluation
for suspected cardiac source of thromboembolism (25.8%), (2)
suspected infective endocarditis (23.5%), (3) evaluation of native-
prosthetic valve (22.3%), (4) before cardioversion of atrial fibril-
lation (11.7%), and (5) “other” (16.4%).
The atherosclerotic risk factors considered in this study were
diabetes mellitus, hypertension, and hypercholesterolemia. Diabe-
tes was defined as hyperglycemia requiring pharmacologic ther-
apy. Hypertension was defined as either a systolic or diastolic
increase in blood pressure (140/90 mm Hg) or ongoing antihy-
pertensive pharmacologic therapy. Hypercholesterolemia was de-
fined as a total cholesterol level of greater than 200 mg/dL.
Echocardiographic Studies
All intraoperative TEE studies were performed by cardiologists
experienced in intraoperative TEE (DW, YS, AS) using a 3.7/5- or
4/7-MHz multiplane transducer of Phillips (Andover, Mass) or 6T
General Electric Vingmed Ultrasound (Harten, Norway). The ul-
trasonographs used were Agilent 5500 or Vivid 3 Premium digital
cardiovascular ultrasound scanners. Each study was recorded on
super-VHS tape. Severe AS was defined as a reduction in valve
TABLE 1. Clinical characteristics and prevalence of aortic
atheromas in the AS group and control subjects
Characteristic
AS group
(n  91)
Control
group
(n  91)
P
value
Age (y) 71.9  9.4 70.4  8.4 NS
Male sex (%) 55 59 NS
Hypertension (%) 48 44 NS
Hypercholesterolemia (%) 29.7 31.9 NS
Diabetes (%) 18.7 16.5 NS
Aortic atheromas (3 mm) 77 (85%) 34 (37%) .001
Complex atheromas 43 (47%) 8 (9%) .001
AS, Aortic stenosis; NS, not significant.area to less than 1 cm2 according to the American College of
30 The Journal of Thoracic and Cardiovascular Surgery ● July 2Cardiology/American Heart Association guidelines8 or mean gra-
dient of greater than 50 mm Hg across the aortic valve.
After complete cardiac examination, aortic images were ob-
tained by rotating the transducer posteriorly and advancing it to the
distal esophagus. Then it was slowly withdrawn to obtain images
from the distal thoracic aorta to the aortic arch. The ascending
aorta was imaged in the midesophageal window at the level of the
long axis of the aortic valve (120°-160°). The aortic intima was
evaluated for changes in thickening, protrusion, mobile compo-
nents, or ulceration. Aortic atheroma (AA) was defined as local-
ized intimal thickening of 3 mm or greater. A lesion was consid-
ered complex according to the presence of 1 or more of the
following: (1) thickening of the intima extending 5 mm or more
into the aortic lumen, (2) disruption or irregularities of the intimal
surface (ulceration), (3) mobile component of the atheroma, and
(4) protruding atheroma.
Statistical Analysis
Numeric values are reported as means  SD or as a proportion of
the sample size. Comparisons between the study and control
groups were made with 2 analysis for categorical data and the
Student t test for continuous data.
Results
The clinical characteristics and prevalence of AAs in the 2
groups are shown in Table 1. No differences were found
between the groups regarding risk factors for atherosclero-
sis. The cause of AS was degenerative in 59 (64.8%) pa-
tients, rheumatic in 14 (15.3%) patients, bicuspid in 6
(6.6%) patients, and undetermined in 12 (13.1%) patients.
Table 2 shows the prevalence of AAs in the AS group
according to the cause of the disease. The AS group had
significantly higher rates of AAs (85% vs 37%, P  .001)
and complex atheromas (47% vs 9%, P  .001) compared
with the control group. In the AS group the vast majority of
AAs were localized in the aortic arch (60 [66%] patients,
with 50% being complex atheromas) and in the descending
aorta (70 [77%] patients, with 45% being complex athero-
mas); in only 4 (4.4%) patients, the AAs were localized in
the ascending aorta (50% complex atheromas). Forty-four
(48.3%) patients in the AS group underwent concomitant
coronary artery bypass grafting, and in 5 of them it was a
redo procedure. Four (4.4%) patients experienced a periop-
TABLE 2. Prevalence of aortic atheromas in the AS group
according to the main causes of the disease
Degenerative
AS
(n  59)
AS of other
causes
(n  32)
P
value
Aortic atheromas (3 mm) 53 (89.9%) 25 (78.1%) NS
Complex atheromas 35 (59.3%) 8 (25.0%) .004
AS, Aortic stenosis; NS, not significant.erative stroke, and in 3 of them complex atheromas in the
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was 1.1%.
Discussion
To the best of our knowledge, this is the first clinical report
showing a strong and significant association between the
presence of severe AS and AAs on echocardiography. Our
findings further support the hypothesis of AS being the
result of an atherosclerotic-like process. These data might
have important implications in the clinical management of
this common disease. Calcific AS is a progressive valvular
disease with a high prevalence and, despite the excellent
outcome of aortic valve replacement,1,9 still remains a sig-
nificant cause of morbidity and mortality.
Once thought to be a degenerative and age-related con-
dition, several studies in the recent years have shown con-
vincing evidence that calcific AS is the consequence of an
active inflammatory process with some similarities to
atherosclerosis.2,10
Otto and colleagues3 have shown that the early lesion of
degenerative AS is an active inflammatory process charac-
terized by means of lipid deposition, macrophages, and
T-cell infiltration similar to that seen in the atherosclerotic
plaque. Moreover, risk factors for arterial atherosclerosis
(ie, male sex, tobacco use, hypercholesterolemia, hyperten-
sion, and diabetes mellitus) have all been associated with
the development and more rapid progression of AS.7,11-13
The combination of clinical findings and experimental ob-
servations support the hypothesis that calcific degenerative
AS is the result of an active inflammatory cellular process,
an atherosclerosis-like process involving the aortic valve.
Our group was the first to report a strong and significant
association between the presence of aortic valve calcifica-
tion and AAs in a group of 96 patients who underwent TEE
for different causes. Simple atheromas (3 mm) were found
in 86% versus 30% and complex atheromas in 69% versus
18% in the aortic valve calcification group compared with
the control subjects.5
Agmon and associates,14 in a population-based study of
381 subjects, demonstrated that multiple risk factors (age,
male sex, hypertension, obesity, and homocystein levels)
and aortic atherosclerosis evidenced by means of echocar-
diography of the aorta were associated with aortic valve
sclerosis.
Several retrospective studies have suggested that aggres-
sive treatment with lipid-lowering agents (statins) might
slow the progression of valvular calcification.15-17 Novaro
and coworkers,15 in a retrospective study of 174 patients
with mild-to-moderate calcific AS, showed that statin use
was a significant independent predictor of a smaller de-
crease in valve area and a lesser increase in peak gradient
during a mean follow-up of 21 months. Shavelle and asso-
ciates,17 in a retrospective analysis of 65 patients with
The Journal of Thoraccalcific AS, showed that statin treatment was associated
with a 63% lower rate of aortic valve calcium accumulation,
as measured by means of electron-beam computed tomog-
raphy. Future prospective randomized trials will be required
to establish the potential benefit of these agents in slowing
the progression of AS and whether it might be helpful in the
advanced stage of this disease.
Aortic valve replacement is still the mainstay of therapy
for symptomatic severe AS. The operative mortality for AS
has dramatically decreased in recent years, being around
3.1% nowadays.1 However, the operative risk might be
higher in the elderly and in the presence of comorbidities,
such as coronary artery disease, renal disease, and cerebro-
vascular disease. Embolic stroke occurs in 2% to 7% of
patients during cardiac surgery involving cardiopulmonary
bypass, especially in the elderly.18,19 Furthermore, in one
series patients with aortic arch atheromas had a significantly
higher incidence of perioperative stroke than did those
without atheromas (15% vs 2%).20 In another study of 268
patients who underwent TEE, the presence of aortic arch
atheromas of 5 mm or larger increased the perioperative
stroke rate by 6 times and more than doubled the in-hospital
mortality after heart surgery.21 The incidence of periopera-
tive stroke in our study (4 [4.4%] patients) is in accordance
with that found in the literature; however, it is remarkable
that complex aortic arch atheromas were found in 3 of 4 of
these patients, raising the suspicion of a cause-event link.
Our findings might have important practical implications
in the management of patients with severe AS. Taking into
account that more than half of the patients with severe AS
who are referred to surgical intervention are more than 70
years old and that a third of them require concomitant
coronary bypass grafting (a factor that almost doubles the
operative mortality),1 we suggest that the presence of AAs
should be taken into account when analyzing the risk/benefit
ratio for these patients when aortic valve replacement is
contemplated. We consider TEE to be the best tool for
evaluating the presence and complexity of AAs. Therefore
we suggest that TEE might be performed as part of the
preoperative evaluation of a selected group of patients with
severe AS who do not have strong indications for aortic
valve replacement, such as elderly patients with no or equiv-
ocal symptoms and with mild findings during exercise test-
ing or patients with concomitant comorbidities. This might
provide patients and surgeons with important information
regarding the presence of AAs that might expose patients to
a higher risk of stroke and perioperative mortality.
In conclusion, there is a strong association between the
presence of severe AS and the presence and severity of
AAs, suggesting that AS might be a manifestation of the
atherosclerotic process. These findings imply that (1) ag-
gressive atherosclerotic risk-factor modification for patients
with AS might be advisable and (2) consideration of eval-
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CDuation of the aorta by means of TEE before aortic valve
replacement in selected patients might be helpful.
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